The invalidation of the patent eliminates a key catalyst for Enanta's valuation. Monitor whether Enanta files an appeal to the UPC Court of Appeal or pursues parallel litigation in individual EU national courts. Also watch for any impact on Enanta's other patent enforcement efforts.
Price Chart
Executive Summary
The Unified Patent Court (UPC) of the European Union ruled that Enanta's European Patent No. EP 4 051 265 is invalid, terminating the company's patent infringement lawsuit against Pfizer over Paxlovid. The decision eliminates any potential royalty stream from Paxlovid sales in the 18 EU member states covered by the UPC, representing a material setback to Enanta's litigation-driven revenue strategy.
Key Facts
- Enanta filed a patent infringement action against Pfizer in the UPC regarding Paxlovid (nirmatrelvir/ritonavir) in 18 EU member states.
- Pfizer counterclaimed for revocation of European Patent No. EP 4 051 265.
- A hearing was held on September 29, 2026.
- On October 29, 2026, the UPC concluded that the 265 Patent is invalid and the infringement action is unfounded.
- The decision is final within the UPC system; no appeal is mentioned in the filing.
Financial Impact
Loss of potential royalty revenue from Paxlovid sales in 18 EU countries; no specific damages or royalty figures were disclosed in the filing.
Risk Factors
- No further revenue from Paxlovid-related patent litigation in the UPC jurisdiction.
- Potential negative precedent for Enanta's other patent claims if the invalidity reasoning applies to related patents.
- No appeal or alternative legal recourse mentioned in the filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-437774 |
| Document: 0001193125-26-437774-index-headers.html | 0001193125-26-437774 |
| Document: 0001193125-26-437774-index.html | 0001193125-26-437774 |
| Document: 0001193125-26-437774.txt | 0001193125-26-437774 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $11.15 | awaiting T+20 | awaiting T+20 | $10.71 (+3.95%) |
Oct 28, 2026 4d ago | 8-K | $11.55 | awaiting T+20 | awaiting T+20 | $10.71 (−7.27%) |
Oct 27, 2026 5d ago | SC 13G | $11.55 | awaiting T+20 | awaiting T+20 | $10.71 (−7.27%) |
Aug 10, 2026 11w ago | 8-K | $13.52 $13.24 | ▼ −2.07% | ▼ −1.01% | $10.71 (−20.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers